Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BLINATUMOMAB Cause Visual acuity reduced? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Visual acuity reduced have been filed in association with BLINATUMOMAB (BLINCYTO). This represents 0.1% of all adverse event reports for BLINATUMOMAB.

5
Reports of Visual acuity reduced with BLINATUMOMAB
0.1%
of all BLINATUMOMAB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Visual acuity reduced From BLINATUMOMAB?

Of the 5 reports, 2 (40.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.

Is Visual acuity reduced Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BLINATUMOMAB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does BLINATUMOMAB Cause?

Pyrexia (1,064) Acute lymphocytic leukaemia recurrent (977) Cytokine release syndrome (952) Off label use (590) Death (588) Neurotoxicity (530) Drug ineffective (345) Headache (335) Neutropenia (265) Febrile neutropenia (262)

What Other Drugs Cause Visual acuity reduced?

RANIBIZUMAB (1,342) INSULIN LISPRO (1,172) AFLIBERCEPT (993) BELANTAMAB MAFODOTIN (708) BEVACIZUMAB (451) DIMETHYL (440) INSULIN GLARGINE (438) INTERFERON BETA-1A (396) INSULIN HUMAN (393) BROLUCIZUMAB-DBLL (365)

Which BLINATUMOMAB Alternatives Have Lower Visual acuity reduced Risk?

BLINATUMOMAB vs BLONANSERIN BLINATUMOMAB vs --BLOOD-COAGULATION FACTOR VIII FUSION PROTEIN WITH IMMUNOGLOBULIN G1 , ,-BIS WITH IMMUNOGLOBULIN G1 BLINATUMOMAB vs BOCEPREVIR BLINATUMOMAB vs BOCOCIZUMAB BLINATUMOMAB vs BONIVA

Related Pages

BLINATUMOMAB Full Profile All Visual acuity reduced Reports All Drugs Causing Visual acuity reduced BLINATUMOMAB Demographics